A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs AMG 529 (Primary) ; AMG 529 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 28 Sep 2017 Planned End Date changed from 3 Nov 2017 to 6 Nov 2017.
- 28 Sep 2017 Planned primary completion date changed from 3 Nov 2017 to 6 Nov 2017.
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.